SCHEMBL14896979

SCHEMBL14896979

CN1CCN(c2ccc3ncc(C(=O)Nc4cccnc4)n3n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 2/20 0.49
▸ NAMPT P43490 5/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.47
▸ LRRK2 Q5S007 1/20 0.47
▸ RAB9A P51151 2/20 0.46
▸ GSK3B P49841 3/20 0.44
▸ CCNE2 O96020 2/20 0.44
▸ CCNE1 P24864 2/20 0.44
▸ CDK2 P24941 2/20 0.44
▸ KDM1A O60341 1/20 0.44
▸ RCOR1 Q9UKL0 1/20 0.44
▸ DRD2 P14416 2/20 0.44
▸ DRD4 P21917 2/20 0.44
▸ DRD3 P35462 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897368 0.91 IRAK4 (0.46) IRAK4NAMPTSMN1; SMN2ALDH1A1L3MBTL1
SCHEMBL14897625 0.88 SMN1; SMN2 (0.49) IRAK4NAMPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL14897193 0.86 PTPN11 (0.47) IRAK4NAMPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL14897743 0.86 IRAK4 (0.45) IRAK4NAMPTSMN1; SMN2ALDH1A1GSK3B
SCHEMBL14897264 0.84 IRAK4 (0.47) IRAK4NAMPTSMN1; SMN2ALDH1A1RAB9A
SCHEMBL14897446 0.84 IRAK4 (0.49) IRAK4SMN1; SMN2ALDH1A1L3MBTL1RAB9A
SCHEMBL14897106 0.84 NAMPT (0.43) IRAK4NAMPTSMN1; SMN2ALDH1A1KDM1A
SCHEMBL14897490 0.83 IRAK4 (0.45) IRAK4NAMPTSMN1; SMN2ALDH1A1GSK3B
SCHEMBL16193116 0.83 IRAK4 (0.49) IRAK4NAMPTSMN1; SMN2ALDH1A1GSK3B
SCHEMBL14897155 0.83 NAMPT (0.46) IRAK4NAMPTSMN1; SMN2ALDH1A1KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 3168/4885NAMPT 44/4885SMN1; SMN2 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback